Fresenius Kabi USA Recalls 5.3 Million Vials of Ketorolac Tromethamine Due to Particulate Matter
Fresenius Kabi USA, LLC initiated a Class I recall for 5,314,400 vials of Ketorolac Tromethamine Injection, USP, 30 mg per mL, due to particulate matter. This significant event, active from April 2020 to October 2023, posed substantial supply chain risks and patient safety concerns across the USA and Puerto Rico, demanding immediate action from procurement and regulatory teams to ensure continuity of critical injectable pain management therapies.
FDA Class I Recall: Particulate Matter in Fresenius Kabi's Ketorolac Tromethamine Injection
On April 20, 2020, Fresenius Kabi USA, LLC initiated a voluntary Class I recall, designated D-1296-2020, for its Ketorolac Tromethamine Injection, USP, 30 mg per mL. This critical action was prompted by the discovery of particulate matter within reserve sample vials at the firm's Lake Zurich, IL facility. For procurement directors and regulatory affairs heads, a Class I classification signifies the most severe level of recall, indicating that there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death. The presence of particulate matter in an injectable drug, particularly one administered intravenously or intramuscularly, presents immediate and severe risks to patient safety, including vascular occlusion, phlebitis, pulmonary emboli, and allergic reactions. This event underscores the imperative for robust quality control systems throughout the manufacturing process of sterile injectable pharmaceuticals. The recall encompassed a substantial volume, specifically 5,314,400 vials, distributed across the USA and Puerto Rico, highlighting a significant disruption to the supply chain for this widely used non-steroidal anti-inflammatory drug (NSAID). The recall’s termination on October 16, 2023, after more than three years, indicates a protracted period of market uncertainty and potential supply strain for healthcare providers relying on this essential medication.
Fresenius Kabi USA's Role and the Impact on Ketorolac Tromethamine Supply
Fresenius Kabi USA, LLC, based in Lake Zurich, Illinois, is a significant player in the global market for generic injectable pharmaceuticals. This recall specifically targeted their Ketorolac Tromethamine Injection, USP, 30 mg per mL, a human prescription drug approved under ANDA075784. The product, identified by NDCs 63323-161 and 63323-162, is crucial for the short-term management of moderate to severe acute pain, administered via intramuscular or intravenous routes. For business development executives and supply chain VPs, the recall of over 5.3 million vials of such a foundational pain management drug represents a considerable market void and a challenge for healthcare systems to maintain continuity of care. The broad distribution pattern, covering the entire USA and Puerto Rico, meant that a vast network of hospitals, clinics, and pharmacies were directly affected. This incident necessitates a thorough review of supplier qualification processes and diversification strategies to mitigate reliance on single-source manufacturers for critical medications. The extended duration of the recall, from its initiation in April 2020 to its termination in October 2023, further amplified the potential for prolonged shortages and the need for agile procurement responses to secure alternative supplies of Ketorolac Tromethamine or suitable therapeutic equivalents.
Supply Chain Vulnerabilities and Market Repercussions of a Major Injectable Recall
The recall of 5,314,400 vials of Ketorolac Tromethamine Injection by Fresenius Kabi USA, LLC exposed significant vulnerabilities within the pharmaceutical supply chain, particularly for high-volume injectable products. For procurement directors, this event underscores the critical importance of robust supplier quality agreements and continuous monitoring, especially when dealing with Class I products where quality deviations can have life-threatening implications. The nationwide distribution across the USA and Puerto Rico meant that a substantial portion of the market for this specific pain management therapy faced immediate disruption. Healthcare systems had to swiftly implement contingency plans, including identifying alternative suppliers or therapeutic substitutes, to prevent patient care interruptions. The recall's prolonged status, spanning over three years from April 20, 2020, to October 16, 2023, created sustained market instability. This extended period required consistent vigilance from supply chain VPs to manage inventory, communicate with stakeholders, and navigate the complexities of sourcing a critical drug from a potentially constrained market. Such events highlight the need for proactive risk assessment, including evaluating the resilience of manufacturing processes and the depth of the supplier base for essential medicines, to safeguard against future supply shocks.